Radio-immunothérapie du lymphome folliculaire: un pas vers la guérison [Radioimmunotherapy of follicular lymphoma: a step towards cure?]

Details

Serval ID
serval:BIB_86BDF15B8BF8
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Radio-immunothérapie du lymphome folliculaire: un pas vers la guérison [Radioimmunotherapy of follicular lymphoma: a step towards cure?]
Journal
Bulletin du cancer
Author(s)
Ketterer N., Bischof Delaloye A., Helg C., Luthi F., Buchegger F.
ISSN
1769-6917[electronic]
Publication state
Published
Issued date
2007
Volume
94
Number
9
Pages
799-806
Language
french
Notes
Publication types: English Abstract ; Journal Article ; Review - Publication Status: ppublish
Abstract
Advanced stage follicular lymphoma is incurable by conventional treatment. Important progress has been observed with the development of new therapies based on monoclonal antibodies and on the use of radioimmunotherapy (RIT) in the treatment of non-Hodgkin lymphomas (NHL). Rituximab in combination with chemotherapy in the upfront setting significantly improved treatment outcome as compared with chemotherapy alone. Different studies also indicate that RIT has an important role in the management of NHL and could be beneficial in combination with chemotherapy. These two new treatment options have clearly distinctive mechanisms of action, rituximab being an exclusively biological treatment and RIT adding targeted systemic radiation therapy. Both RIT and the unlabeled antibody treatments might be further improved by different strategies including repetition of RIT or combination of different antibodies. We present here our experience with RIT using 131I-tositumomab (Bexxar) and discuss different topics regarding RIT, like the use of different antibodies, the best choice of the radioisotope or the place of radio-imaging. From the therapeutic point of view, we argue that the debate should not be as to which one among antibody immunotherapy or RIT should be best added to chemotherapy, but that all three treatments might be optimally combined with the aim to get the highest chance of cure for advanced stage follicular lymphoma.
Keywords
Animals, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Bone Marrow Diseases, Clinical Trials as Topic, Combined Modality Therapy, Humans, Lymphoma, Follicular, Mice, Radioimmunotherapy, Radiometry, Radiopharmaceuticals, Radiotherapy Dosage, Treatment Outcome
Pubmed
Web of science
Create date
25/01/2008 11:21
Last modification date
20/08/2019 14:46
Usage data